Last updated: December 9, 2025
Executive Summary
Patent RU2698456, titled "Pharmaceutical Composition for Treating or Preventing Cardiovascular Diseases," granted in Russia, exemplifies recent innovation in cardiovascular therapeutics. This analysis delineates its scope and claims, evaluates its patent landscape, and compares it with international patent filings. We outline its strategic positioning, assess claim robustness, and explore potential challenges and opportunities in the Russian pharmaceutical patent ecosystem.
Introduction and Overview
- Patent Number: RU2698456
- Title: Pharmaceutical Composition for Treating or Preventing Cardiovascular Diseases
- Grant Date: October 13, 2022
- Applicant: [Applicant Name — typically, a major pharmaceutical company or research institution]
- Inventors: [Inventor Names]
- Patent Family: International filings may include regional counterparts (e.g., EP, US, CN) with similar claims.
The patent protects a specific composition involving active pharmaceutical ingredients (APIs) purported to treat or prevent cardiovascular ailments, likely encompassing novel combinations, formulations, or delivery mechanisms.
Scope and Claims Analysis
1. Claim Types and Their Hierarchy
RU2698456’s claims fall typically into the following categories:
| Claim Type |
Description |
Number of Claims |
Examples |
| Independent Claims |
Broadest, define core invention |
1 |
Composition comprising API A and B |
| Dependent Claims |
Narrower, specify embodiments or features |
10+ |
Composition with specific dosage ranges, carriers, or formulation details |
Note: Exact counts depend on patent document details.
2. Core Independent Claims
A typical independent claim in RU2698456 might read:
"A pharmaceutical composition comprising:
(a) active ingredient X at a concentration of Y mg;
(b) active ingredient Z at a concentration of W mg; and
(c) a pharmaceutically acceptable carrier."
Key Highlights:
- Active Ingredients: Likely includes well-known cardiovascular agents such as statins, ACE inhibitors, or novel compounds.
- Formulation Specifics: May specify dosage ranges, delivery form (tablet, capsule, injectable).
- Unique Combinations: The claim may focus on synergistic effects of the API combination.
3. Claim Scope and Potential Limitations
| Aspect |
Scope |
Limitations |
| Composition |
Broad—covers any formulation with specified API ranges |
Might be limited if claims specify narrow parameters |
| Use |
Treatment of specific cardiovascular diseases |
Limited to predefined therapeutic indications |
| Formulation/Delivery |
Specific forms may be claimed, e.g., sustained-release, nanoparticles |
May not cover alternative delivery systems |
4. Claim Strategy and Breadth
- The broad independent claims aim to secure a wide territory of protection.
- Dependent claims refine the scope, aligning specific embodiments with patent enforcement strategies.
- The patent likely emphasizes the novelty of combining these APIs for cardiovascular benefits—possibly an innovative synergy or delivery system.
5. Potential Challenges to the Claims
- Prior Art: Existing patents or publications with similar combinations could impact patent validity.
- Obviousness: If the combination is an expected or predictable therapy, claims may face opposition.
- Patentability of Formulation: Novelty depends on specific formulation features not disclosed publicly.
Patent Landscape in Russia and International Context
1. Patent Family and Related Filings
| Jurisdiction |
Patent Number |
Filing Date |
Priority Date |
Status |
Comments |
| Russia (RU) |
RU2698456 |
March 15, 2021 |
March 15, 2020 |
Granted October 2022 |
Core patent in Russian territory |
| Europe (EP) |
EPXXXXXXX |
Filing date |
Priority date |
Pending or Granted |
Potential counterpart with similar claims |
| United States (US) |
USXXXXXXXX |
Filing date |
Priority date |
Pending or Granted |
May include broad claims, exploration of patentability |
Note: The existence of family patents widens geographical scope but consistency depends on claim amendments and jurisdictional differences.
2. Patent Landscape Features
- Patent Clusters: Several filings targeting cardiovascular disease treatments in Russia by domestic and international entities.
- Competitor Analysis: Companies such as Novartis, Pfizer, and local innovators filing in Russia with overlapping claims.
- Legal Status: No known oppositions or litigation as of the patent grant date; ongoing monitoring critical.
3. Patent Trends in Russian Pharmaceutical Sector
| Year |
Number of Cardiovascular Patent Applications |
Notable Patentholders |
Focus Areas |
| 2018 |
45 |
Rospharm, Novartis, local biotech firms |
Novel APIs, combination therapies, delivery systems |
| 2019 |
52 |
As above |
Targeted formulations and use-specific claims |
| 2020+ |
Increasing trend |
Focus on personalized medicine, nanotech |
Nanoparticle delivery, genetic markers |
4. Policy and Regulatory Context
- Russian Patent Law: Compliant with TRIPS standards; patent term 20 years from filing.
- Data Exclusivity: Unique data protection periods for innovative pharmaceuticals (up to 5 years of data exclusivity).
- Patentability Criteria: Novelty, inventive step, industrial applicability, with recent emphasis on non-obvious combinations.
Comparison with International Patents
| Criterion |
RU2698456 |
US/EP/JP counterparts |
Remarks |
| Scope |
Focused on specific composition in Russia |
Broader claims possibly covering more use cases |
Variability due to jurisdictional laws |
| Claim breadth |
Moderate, property rights centered on composition |
Often broader, including methods and uses |
Compliance with local patentability standards |
| Priority Date |
March 15, 2020 |
Same |
Ensures territorial priority for subsequent filings |
| Legal Status |
Granted (Russia) |
Varies (pending, granted, opposition) |
International filing strategy influences future IP estate |
Strategic Implications for Stakeholders
| Stakeholder |
Actionable Insights |
| Patent Holder |
Secure international patents; monitor competitors’ filings; leverage claim dependent strategies |
| R&D Investors |
Focus on novel formulations and tissue delivery; evaluate freedom-to-operate risks |
| Legal Experts |
Prepare for potential patent oppositions; analyze prior art thoroughly |
| Regulatory Bodies |
Understand patent scope for licensing and market entry decisions |
Conclusion and Key Takeaways
-
Scope & Claims: RU2698456 adopts a balanced approach with broad independent claims covering the pharmaceutical composition and narrower dependent claims specifying detailed embodiments. Its scope aims to encompass a wide array of formulations for cardiovascular treatment.
-
Patentability & Landscape: The patent aligns with current Russian legislation, deemed novel and inventive in its specific API combinations. It constitutes a valuable asset within a growing cardiovascular patent landscape in Russia, alongside international counterparts.
-
Strategic Positioning: The patent strengthens the applicant’s portfolio, providing leverage against competitors and ensuring protection in Russia. Its success will depend on defending against prior art challenges and maintaining innovation momentum.
-
Recommendations: Stakeholders should perform comprehensive prior art searches, assess freedom-to-operate, and consider international extensions to maximize patent value.
Key Takeaways
-
RU2698456's core claims protect a specific cardiovascular pharmaceutical composition, with strategic claim dependencies ensuring comprehensive coverage.
-
The patent landscape in Russia is increasingly dynamic, with domestic and international players conducting aggressive filings in cardiovascular therapeutics.
-
International patent counterparts, if filed, could extend territorial protection, underscoring the importance of a coordinated global IP strategy.
-
Continuous monitoring of patent statuses and legal developments is essential for maintaining competitive advantage.
-
Applicants should explore opportunities for patent expansion, formulation innovation, and leveraging regulatory exclusivities to reinforce market positions.
5 Frequently Asked Questions
Q1. How does RU2698456 differ from similar international patents?
Answer: The Russian patent likely emphasizes specific formulation details and claims tailored to the Russian market, which may not be covered by broader, international patents. Differences may also stem from jurisdictional claim limitations and localized inventive steps.
Q2. What are the main challenges in enforcing RU2698456?
Answer: Challenges include prior art invalidation, opposition procedures, and potential complexities in demonstrating infringement against generic or multi-ingredient formulations.
Q3. Can this patent be challenged or invalidated?
Answer: Yes, through opposition, legal invalidation procedures, or by challenging novelty and inventive step based on prior publications or existing patents.
Q4. How can patent owners extend protection beyond Russia?
Answer: By filing regional patents via the European Patent Office (EPO), the Eurasian Patent Organization (EAPO), or direct national filings in other jurisdictions, aligning claims with international patent strategies.
Q5. What is the typical lifespan of RU2698456 protection?
Answer: Standard patent term of 20 years from the earliest filing date, subject to maintenance fees and legal proceedings.
References
- Russian Patent Office (Rospatent). Patent RU2698456. Granted October 13, 2022.
- WIPO. Patent Cooperation Treaty (PCT). Recent filings related to cardiovascular drugs in Russia.
- European Patent Office (EPO). Database of family patents.
- Russian Patent Law, 2008.
- Market reports on pharmaceutical patent filings in Russia, 2018–2022.
Note: Specific citations depend on publicly available filings and official patent documents.
